Let’s talk Ozempic...again!

Gabe and Annie Rench are back for round two on the biggest trend in health and fitness right now: GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound. A year after their first Ozempic episode blew up, they revisit the topic with fresh eyes — why so many people (maybe one in three women, by their guess) feel like they have no other option, what the British Medical Journal's newest research says about weight regain after stopping, and why "just eat less" is the most reductionist advice in modern medicine.

💦 IN THIS EPISODE:

What GLP-1/GIP agonist drugs (semaglutide, tirzepatide, and the upcoming retatrutide) actually do in your body, chemically speaking

Five real reasons so many people feel like a GLP-1 is their only option — from ignored root-cause health drivers to decades of yo-yo dieting to women's hormones being flat-out misunderstood by modern medicine

Annie's own years-long thyroid journey, and why "just eat less, move more" advice fails so many people

A brand-new British Medical Journal meta-analysis on rapid weight regain after stopping these drugs — and Annie's two biggest unanswered concerns about staying on them long-term

Who Annie actually thinks these drugs are for, and the harm-reduction approach (lowest dose, an exit strategy, working the fundamentals alongside it) she'd want you to take if you're going to use one

⏱️ TIMESTAMPS

00:00 – Intro & sponsor read (Kings Ridge Elderberry Farm)

00:47 – Fight Laugh Feast Conference announcement & welcome to Waterbreak

01:50 – Why we're doing an Ozempic round two

02:35 – Just how many people are actually on these drugs right now